Search

Companies planning to develop and commercialize medical devices or diagnostics face a challenging financing, regulatory, reimbursement and liability environment. Saul Ewing attorneys are experienced in helping medical device and diagnostic companies navigate these challenges. Many members of our...

Saul Ewing's First Amendment and Religious Land Use attorneys counsel private clients on all aspects of religious land use freedoms and protections, including application and enforcement of the First Amendment, the Religious Land Use and Institutionalized Persons Act (RLUIPA), and the Florida...

Handling the Challenges of a Rapidly Evolving Industry From the rise of smart cities and 5G to blockchain and machine-to-machine communication, next generation wireless technologies are reshaping our world. Participants in the telecommunications and digital infrastructure industry have a critical...

Class actions filed against a company can quickly turn low-stake claims into litigation that can critically impact operations and create large exposures. Saul Ewing’s Class Actions Litigation Group guides clients through all phases of class action litigation defense, focusing on early-case...

Saul Ewing’s Litigation Department features approximately 200 attorneys across 18 offices. We handle a wide range of matters including complex business and commercial disputes, bet-the-company legal proceedings, and high-profile cases in state and federal courts and Alternative Dispute Resolution...

Industry-Specific, Business-Focused Legal Advice Increased pricing pressure combined with a rise in generic competition and continued regulatory uncertainty have squeezed the margins of life sciences companies. Helping navigate this ever-shifting terrain, Saul Ewing’s Life Sciences Practice consists...

Counsel From the Earliest Stage of Development Through Disposition of Projects Throughout the continuum of financing, acquiring, developing, leasing and selling real estate are a multitude of complexities to address and challenges to overcome—from regulatory hurdles and shifting capital stacks to...